Theratechnologies Inc. (THTX)
NASDAQ: THTX · Real-Time Price · USD
1.400
+0.065 (4.64%)
At close: Apr 1, 2025, 4:00 PM
1.410
+0.010 (0.71%)
After-hours: Apr 1, 2025, 4:41 PM EDT
Theratechnologies Revenue
In the fiscal year ending November 30, 2024, Theratechnologies had annual revenue of $85.87M with 5.02% growth. Theratechnologies had revenue of $25.00M in the quarter ending November 30, 2024, with 6.61% growth.
Revenue (ttm)
$85.87M
Revenue Growth
+5.02%
P/S Ratio
0.77
Revenue / Employee
$833,650
Employees
103
Market Cap
65.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2024 | 85.87M | 4.10M | 5.02% |
| Nov 30, 2023 | 81.76M | 1.71M | 2.13% |
| Nov 30, 2022 | 80.06M | 10.23M | 14.66% |
| Nov 30, 2021 | 69.82M | 3.77M | 5.71% |
| Nov 30, 2020 | 66.05M | 2.84M | 4.49% |
| Nov 30, 2019 | Pro | Pro | Pro |
| Nov 30, 2018 | Pro | Pro | Pro |
| Nov 30, 2017 | Pro | Pro | Pro |
| Nov 30, 2016 | Pro | Pro | Pro |
| Nov 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
THTX News
- 6 days ago - Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy - GlobeNewsWire
- 20 days ago - Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI - GlobeNewsWire
- 20 days ago - Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV - GlobeNewsWire
- 4 weeks ago - Theratechnologies Inc. (THTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 - GlobeNewsWire
- 6 weeks ago - Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 6 weeks ago - Theratechnologies Resumes Distribution of EGRIFTA SV® - GlobeNewsWire
- 2 months ago - Theratechnologies Provides Update on EGRIFTA SV® Supply - GlobeNewsWire